Related Experiment Video
Updated: Jan 10, 2026
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Ex vivo qualitative and quantitative analysis of fluorescently-labeled Hsp90 drug in human tumors
Sarah J Backe1, Dimitra Bourboulia2, Mark R Woodford2
1Department of Urology, SUNY Upstate Medical University, Syracuse, NY, 13210, USA; Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, 13210, USA.
Abstract:
Heat shock protein 90 (Hsp90) stabilizes numerous oncogenic proteins, making it a key therapeutic target in cancer. This protocol details an ex vivo method using freshly resected human renal cell carcinoma tissues to evaluate fluorescently labeled Hsp90 inhibitor ganetespib accumulation in tumor versus normal tissue. By preserving the native tumor architecture, this method offers a physiologically relevant alternative to xenograft models. This protocol combines flow cytometry and confocal microscopy to quantitatively and visually assess ganetespib uptake, providing insight into drug distribution and therapeutic response in human cancers. For complete details on the use and execution of this protocol, please refer to Dunn et al. and Woodford et al.
Insights
This study presents an ex vivo method to assess Heat Shock Protein 90 (Hsp90) inhibitor ganetespib accumulation in human renal cell carcinoma. This approach offers a physiologically relevant alternative to animal models for cancer drug development.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Heat shock protein 90 (Hsp90) is crucial for stabilizing oncogenic proteins in cancer.
- Targeting Hsp90 presents a promising therapeutic strategy for various cancers.
- Understanding drug distribution in native tumor tissue is vital for effective cancer treatment.
Purpose of the Study:
- To develop and validate an ex vivo protocol for evaluating Hsp90 inhibitor ganetespib accumulation in human renal cell carcinoma.
- To compare ganetespib uptake in tumor tissue versus adjacent normal tissue.
- To provide a physiologically relevant model for assessing drug efficacy and distribution.
Main Methods:
- Utilized freshly resected human renal cell carcinoma tissues for ex vivo analysis.
- Employed fluorescently labeled ganetespib to track inhibitor accumulation.
- Combined flow cytometry and confocal microscopy for quantitative and visual assessment of drug uptake.
- Preserved native tumor architecture to maintain physiological relevance.
Main Results:
- Demonstrated the feasibility of quantifying ganetespib accumulation in ex vivo human tumor samples.
- Visualized differential drug distribution between tumor and normal renal tissues.
- Established a method to assess drug penetration and retention within the native tumor microenvironment.
Conclusions:
- The developed ex vivo protocol provides a valuable tool for evaluating Hsp90 inhibitors like ganetespib in human cancer.
- This method offers a relevant alternative to traditional xenograft models for preclinical drug assessment.
- Insights into drug distribution can inform therapeutic strategies and predict treatment response in renal cell carcinoma.
